安杰思跌2.03%，成交额4095.04万元，主力资金净流出522.95万元

Core Viewpoint - Anjiasi's stock has experienced a decline recently, with a notable drop in trading volume and a mixed performance in revenue and profit growth [1][2]. Company Overview - Anjiasi Medical Technology Co., Ltd. was established on December 6, 2010, and went public on May 19, 2023. The company is based in Hangzhou, Zhejiang Province, and specializes in the research, development, production, and sales of minimally invasive diagnostic and therapeutic instruments [1]. - The main business revenue composition is as follows: GI category 62.74%, EMR/ESD category 23.26%, ERCP category 11.04%, instruments category 2.21%, and others 0.74% [1]. Financial Performance - For the period from January to September 2025, Anjiasi achieved operating revenue of 459 million yuan, representing a year-on-year growth of 7.51%. However, the net profit attributable to the parent company was 177 million yuan, showing a year-on-year decrease of 10.35% [2]. - Since its A-share listing, Anjiasi has distributed a total of 239 million yuan in dividends [3]. Shareholder Information - As of October 20, 2025, the number of shareholders for Anjiasi was 5,728, an increase of 2.89% from the previous period. The average circulating shares per person decreased by 2.47% to 7,255 shares [2]. - Notable new institutional shareholders include Ping An Low Carbon Economy Mixed A (009878) as the fourth largest shareholder with 850,000 shares, and Hong Kong Central Clearing Limited as the eighth largest shareholder with 420,900 shares [3].